TCGA-55-1592-01A-01R-0946-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 65
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- BILE_ACID_METABOLISM+0.360
- PROTEIN_SECRETION+0.160
- CHOLESTEROL_HOMEOSTASIS+0.150
- FATTY_ACID_METABOLISM+0.140
- KRAS_SIGNALING_DN+0.130
- XENOBIOTIC_METABOLISM+0.110
- HEME_METABOLISM+0.100
- PEROXISOME+0.100
- COAGULATION+0.050
- COMPLEMENT+0.040
Top 10 suppressed
- MYC_TARGETS_V2-0.620
- MYC_TARGETS_V1-0.570
- E2F_TARGETS-0.430
- UNFOLDED_PROTEIN_RESPONSE-0.400
- G2M_CHECKPOINT-0.390
- DNA_REPAIR-0.380
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.380
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.360
- OXIDATIVE_PHOSPHORYLATION-0.350
- PI3K_AKT_MTOR_SIGNALING-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG14 | — | — | 0.867 |
| 2 | C3L-02958 | — | cohortA1 | 0.866 |
| 3 | BS_063ERW0R | pilocytic astrocytoma | — | 0.865 |
| 4 | BS_ME3HKN2C | Ganglioglioma | — | 0.848 |
| 5 | MNG36 | — | — | 0.846 |
| 6 | SRR6013492 | — | cohortA1 | 0.842 |
| 7 | TCGA-67-6217-01A-11R-1755-07 | — | cohortA1 | 0.833 |
| 8 | TCGA-G2-A2EK-01A-22R-A18C-07 | — | — | 0.832 |
| 9 | TCGA-55-A4DG-01A-11R-A24H-07 | — | cohortA1 | 0.830 |
| 10 | BS_TMTV769C | low-grade glioma | — | 0.827 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| BILE_ACID_METABOLISM | 0.360 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.160 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.150 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.130 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.110 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| COAGULATION | 0.050 | Binimetinib | — uncovered |
| COMPLEMENT | 0.040 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.010 | Inavolisib | — uncovered |